Vimarsana
Biggest News Aggregation in the World

Page 6 - Inflammatory Disorders News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Inflammatory Disorders. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Inflammatory Disorders Today - Breaking & Trending Today

Equillium to Present at the JMP Securities Life Sciences Conference - Vimarsana News

Equillium to Present at the JMP Securities Life Sciences Conference

LA JOLLA, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the JMP Securities Life Sciences Conference, a virtual investor event, taking place June 16 and 17, 2021. Bruce Steel, Equillium’s chief executive officer, will provide a high-level overview of itolizumab’s mechanism of action and review each of the ongoing clin

Source: yahoo.com
Anti-inflammatory drugs may cause weaker immune response to Covid-19 vaccine: Study | India News - Vimarsana News

Anti-inflammatory drugs may cause weaker immune response to Covid-19 vaccine: Study | India News

India News: NEW DELHI: Some people who take the drug methotrexate to treat common immune system disorders like rheumatoid arthritis and multiple sclerosis may mou.

Anti-inflammatory drugs may cause weaker immune response to COVID-19 vaccine, says study - Vimarsana News

Anti-inflammatory drugs may cause weaker immune response to COVID-19 vaccine, says study

The study, published in the journal Annals of the Rheumatic Diseases, looked specifically at patients' responses to the Pfizer-BioNTech mRNA Covid-19 vaccine, which the researchers measured by looking at the antibodies produced in each patient by the vaccine.

New Tezepelumab Data Continue To Strengthen Profile For A Broad Population Of Severe Asthma Patients - Vimarsana News

New Tezepelumab Data Continue To Strengthen Profile For A Broad Population Of Severe Asthma Patients

/PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced detailed results for tezepelumab, a potential first-in-class treatment, from the pivotal...

Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA - Vimarsana News

Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA

Share this article Share this article THOUSAND OAKS, Calif., May 10, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced its partner AstraZeneca (NASDAQ:AZN) submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tezepelumab, a potential first-in-class medicine in severe asthma. The submission is supported by positive clinical trial results from the PATHFINDER clinical program including the pivotal NAVIGATOR Phase 3 trial, which demonstrated a statistically significant and clinically meaningful reduction in the annualized asthma exacerbation...